Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004978 · ClinicalTrials.gov registry record · Phase 3
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 4,150
- Enrollment target
NCT00004978 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,150 participants.
The verdict
NCT00004978, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,150 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy. Patients will be followed over a minimum of 4 years to study the long-term effects of rIL-2 on their HIV disease progression. Anti-HIV therapy has been very successful in treating HIV positive patients and in keeping viral load (level of HIV in the blood) low. However, anti-HIV drugs cannot completely rid the body of the virus, and the immune system is never completely restored in HIV positive patients. Doctors hope that giving patients recombinant interleukin-2 (rIL-2) in addition to their anti-HIV therapy will help improve their immune systems and keep them healthier over a longer period of time. rIL-2 is a hormone naturally produced by the body during an immune response to a microbial infection.
Interventions
- DRUG Recombinant interleukin-2 (rIL-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,150 participants |
| Start Date | 2000-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004978
The ClinicalTrials.gov registry entry for NCT00004978 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant interleukin-2 (rIL-2) is the first listed.
NCT00004978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004978 about?
NCT00004978 is a clinical study titled "An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy". The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy. Patients will be followed over a minimum of 4 years to study the long-term effects of rIL-2 on their HIV disease progression. Anti-HIV therapy has ...
What is the current status of trial NCT00004978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,150 participants. The study started on 2000-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00004978?
The interventions under investigation include: Recombinant interleukin-2 (rIL-2) (DRUG).
Who is sponsoring clinical trial NCT00004978?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.